Pharmaceutical Research

, Volume 12, Issue 9, pp 1343–1349 | Cite as

The Pulmonary Absorption of Aerosolized and Intratracheally Instilled rhG-CSF and monoPEGylated rhG-CSF

  • Ralph W. Niven
  • K. Lane Whitcomb
  • Linda Shaner
  • Anna Y. Ip
  • Olaf B. Kinstler


Purpose. The objective of this study was to highlight differences in the pulmonary absorption of a monoPEGylated rhG-CSF and rhG-CSF after intratracheal instillation and aerosol delivery.

Methods. Male Sprague Dawley rats (250 g) were anesthetized and intratracheally instilled (IT) with protein solution or were endotracheally intubated and administered aerosol for 20 min via a Harvard small animal ventilator. A DeVilbiss “Aerosonic” nebulizer containing 5 ml of protein solution at ≈ 3 mg/ml was used to generate aerosol. The volume of protein solution deposited in the lung lobes was estimated to be ≈13 µl after delivery of Tc-99m HSA solutions. The PEGylated proteins consisted of a 6 kDa (P6) or 12 kDa PEG (PI2) linked to the N-terminus of rhG-CSF. rhG-CSF also was administered IT in buffers at pH 4 and pH 7 and in dosing volumes ranging from 100 to 400 µl. Blood samples were removed at intervals after dosing and the total white blood cell counts (WBC) were determined. Plasma was assayed for proteins by an enzyme immuno assay.

Results. The plasma protein concentration v. time profiles were strikingly different for aerosol v. IT delivery. The Cmax values for rhG-CSF and P12 after aerosol delivery were greater than found after IT (Aerosol: 598 ± 135 (ng/ml) rhG-CSF; 182 ± 14 P12 v. IT: 105 ± 12 rhG-CSF; 65.9 ± 5 P12). Similarly, Tmax was reached much earlier after aerosol administration (Aerosol: 21.7 ± 4.8 (min) rhG-CSF; 168 ± 31 P12 v. IT: 100 ± 17 rhG-CSF; 310 ± 121 P12). Estimated bioavailabilities (Flung %) were significantly greater via aerosol delivery than those obtained after IT (Aerosol: 66 ± 14 rhG-CSF; 12.3 ± 1.9 P12 v. IT: 11.9 ± 1.5 rhG-CSF; 1.6 ± 0.1 P12). An increase in circulating WBC counts was induced by all proteins delivered to the lungs. The rate and extent of absorption of rhG-CSF was not influenced by the pH employed nor the instilled volume.

Conclusions. Estimates of bioavailability are dependent upon the technique employed to administer drug to the lungs. Aerosol administration provides a better estimate of the systemic absorption of macromolecules.

aerosols G-CSF lung drug delivery regulation proteins 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. W. Niven, F. D. Lott, and J. M. Cribbs. Pulmonary absorption of recombinant methionyl human granulocyte colony-stimulating factor (r-HuG-CSF) after intratracheal instillation to the hamster. Pharm. Res. 10:1604–1610 (1993).Google Scholar
  2. 2.
    R. W. Niven, F. D. Lott, A. Y. Ip, and J. M. Cribbs. Pulmonary delivery of powders and solutions containing granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm. Res. 11:1101–1109 (1993).Google Scholar
  3. 3.
    R. W. Niven, K. L. Whitcomb, L. Shaner, L. D. Ralph, A. D. Habberfield, and J. V. Wilson. Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF). J. Controlled Release 32:177–189 (1994).Google Scholar
  4. 4.
    J. N. Pritchard, A. Holmes, J. C. Evans, R. J. Evans, and A. Morgan. The distribution of dust in the rat lung following administration by inhalation and by single intratracheal instillation. Environ. Res. 36:268–297 (1985).Google Scholar
  5. 5.
    J. D. Brain, D. E. Knudson, S. P. Sorokin, and M. A. Davis. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 11:13–33 (1976).Google Scholar
  6. 6.
    M. Flavin, M. MacDonald, M. Dolovich, G. Coates, and H. O'Brodovich. Aerosol delivery to the rabbit lung with an infant ventilator. Pediatr. Pulm. 2:35–39 (1986).Google Scholar
  7. 7.
    I. W. Lees and A. N. Payne. Adaption and use of an ultrasonic nebulizer for inhalation studies in laboratory animals. Br. J. Pharmacol. 87:225P (1986).Google Scholar
  8. 8.
    R. W. Niven, A. Y. Ip, S. D. Mittelman, C. Farrar, T. Arakawa, and S. J. Prestrelski. Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization. Int. J. Pharm. 109:17–26 (1994).Google Scholar
  9. 9.
    R. W. Niven, A. Y. Ip, S. Mittelman, S. J. Prestrelski, and T. Arakawa. Some factors associated with the ultrasonic nebulization of proteins. Pharm. Res. 12:53–59 (1995).Google Scholar
  10. 10.
    P. Colthorpe, S. J. Farr, G. Taylor, I. J. Smith, and D. Wyatt. The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm. Res. 9:764–768 (1992).Google Scholar
  11. 11.
    L. S. Schanker, E. W. Mitchell, and R. A. Brown. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab. Disp. 14:79–88 (1986).Google Scholar
  12. 12.
    P. Colthorpe, S. J. Farr, I. J. Smith, D. Wyatt, and G. Taylor. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone. Pharm. Res. 12:356–359 (1994).Google Scholar
  13. 13.
    V. S. Kharasch, T. D. Sweeney, J. Fredberg, J. Lehr, A. I. Damokosh, M. E. Avery, and J. D. Brain. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am. Rev. Respir. Dis. 144:909–13 (1991).Google Scholar
  14. 14.
    D. Collins and Y. Cha. Interaction of recombinant granulocyte colony stimulating factor with lipid membranes: enhanced stability of a water-soluble protein after membrane insertion. Biochemistry 33:4521–6 (1994).Google Scholar
  15. 15.
    G. Dranoff, A. D. Crawford, M. Sadelain, B. Ream, A. Rashid, R. T. Bronson, G. R. Dickersin, C. J. Bachurski, E. L. Mark, J. A. Whitsett, and et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264:713–6 (1994).Google Scholar
  16. 16.
    G. Cox, J. Gauldie, and M. Jordana. Bronchial epithelial cell-derived cytokines (G-CSF and GM-CSF) promote the survival of peripheral blood neutrophils in vitro. Am. J. Respir. Cell Mol. Biol. 7:507–513 (1992).Google Scholar
  17. 17.
    R. Arnold, B. Humbert, H. Werchau, H. Gallati, and W. Koenig. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology 82:126–33 (1994).Google Scholar
  18. 18.
    B. Holma. Effects of inhaled acids on airway mucus and its consequences for health. Environ. Health Perspect. 79:109–13 (1989).Google Scholar
  19. 19.
    F. Komada, S. Iwakawa, N. Yamamoto, H. Sakakibara, and K. Okumura. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 83:863–867 (1994).Google Scholar
  20. 20.
    P. L. Smith, J. Marcello, D. C. Chiossone, D. Orner, and I. J. Hidalgo. Absorption of an RGD peptide (SK&F 106760) following intratracheal administration in rats. Int. J. Pharm. 106:95–101 (1994).Google Scholar
  21. 21.
    B. Holma and P. O. Hegg. pH-and protein-dependent buffer capacity and viscosity of respiratory mucus. Their interrelationships and influence on health. Sci. Total Environ. 84:71–82 (1989).Google Scholar
  22. 22.
    Y. Li, Z. Shao, D. B. DeNicola, and A. K. Mitra. Effect of a conjugated bile salt on the pulmonary absorption of insulin in rats. Eur. J. Biopharm. 39:216–221 (1993).Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Ralph W. Niven
    • 1
  • K. Lane Whitcomb
  • Linda Shaner
  • Anna Y. Ip
  • Olaf B. Kinstler
  1. 1.Amgen Inc.Thousand Oaks

Personalised recommendations